ArticlePloS one2017
Stability of bacteriophages in burn wound care products.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 85 citations in OpenAlex.
- Approaching the post-antibiotic era: phage therapy current practices and future horizons.mBio · 2026Review
- Potential of phage therapy for the treatment of diabetic foot infections.Folia microbiologica · 2026Review
- Designing Multifunctional Antibacterial Hydrogels: A Tri-Pillar Approach Based on Bacteriophages, Hydroxyapatite, and Electrospun Systems.Gels (Basel, Switzerland) · 2026Review
- Expanding the Antimicrobial Toolbox with Therapeutic Viruses: Mechanisms, Pharmaceutical Formulation, and Translational Outlook.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Isolation, characterisation and potential applications of a novel bacteriophage targeting beta-lactam-resistant Staphylococcus saprophyticus.Scientific reports · 2026Article
- Isolation, characterization and genomic analysis of a novel lytic bacteriophage EcoPhCCP1, capable of infecting multiple strains of multidrug-resistantThe Journal of general virology · 2026Article
- Spot-on phage therapy: stable formulations, smarter dosing for topical phage application.Frontiers in cellular and infection microbiology · 2026Review
- Revolutionizing diabetic foot ulcer treatment: phage therapy as a next-generation antimicrobial approach- a review on breaking the cycle of resistance.Journal of diabetes and metabolic disorders · 2025Review
- Engineered Mycoplasma pneumoniae targeting dual-species bacterial biofilms: a novel strategy against infections.NPJ biofilms and microbiomes · 2025Article
- Phage Therapy forAntibiotics (Basel, Switzerland) · 2025Review
- Hydrogels and Microgels: Driving Revolutionary Innovations in Targeted Drug Delivery, Strengthening Infection Management, and Advancing Tissue Repair and Regeneration.Gels (Basel, Switzerland) · 2025Review
- Early Detection, Diagnosis, Prevention, and Treatment of Infection to Avoid Sepsis and Septic Shock in Severely Burned Patients: A Narrative Review.European burn journal · 2025Review
- Novel delivery systems for phages and lysins in the topical management of wound infections: a narrative review.Frontiers in microbiology · 2025Review
- Bacteriophage entrapment strategies for the treatment of chronic wound infections: a comprehensive review.Archives of microbiology · 2024Review
- Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.Nature microbiology · 2024Observational
- Current Knowledge and Perspectives of Phage Therapy for Combating Refractory Wound Infections.International journal of molecular sciences · 2024Review
- Phage Delivery Strategies for Biocontrolling Human, Animal, and Plant Bacterial Infections: State of the Art.Pharmaceutics · 2024Review
- Stability study in selected conditions and biofilm-reducing activity of phages active against drug-resistant Acinetobacter baumannii.Scientific reports · 2024Article
- Evaluation of the Feasibility of Using Commercial Wound Coatings as a Carrier Matrix for Bacteriophages.Sovremennye tekhnologii v meditsine · 2024Article
- An Overview of Diverse Strategies To InactivateEcoSal Plus · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages could be used along with burn wound care products to enhance antimicrobial pressure during treatment. However, some of the components of the topical antimicrobials that are traditionally used for the prevention and treatment of burn wound infection might affect the activity of phages. Therefore, it is imperative to determine the counteraction of therapeutic phage preparations by burn wound care products before application in patients. Five phages, representatives of two morphological families (Myoviridae and Podoviridae) and active against 3 common bacterial burn wound pathogens (Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus) were tested against 13 different products commonly used in the treatment of burn wounds. The inactivation of the phages was quite variable for different phages and different products. Majority of the anti-infective products affected phage activity negatively either immediately or in the course of time, although impact was not always significant. Products with high acidity had the most adverse effect on phages. Our findings demonstrate that during combined treatment the choice of phages and wound care products must be carefully defined in advance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.